Reading MAZE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MAZE free→Reading MAZE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MAZE free→QuarterlyIQ Insights · MAZE
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the “Company”), effective June 1, 2026. Ms. Bachrodt’s resignation was not as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices or on any matter relating…
of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act, whether made before or after the da…
Other Events. On April 21, 2026, Maze Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC as sole underwriter (the “ Underwriter ”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 5,540,000 shares of its common stock (the “ Shares ”) and (b) pre-funded warrants to purchase 850,000 shares of its common stock (the “ Pre-Funded Warrants ”) to the Underwriter (th…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 24, 2026, the Board of Directors (the “Board”) of the Company appointed Neil Kumar as a Class I director, effective March 27, 2026 (the “Appointment Date”). Dr. Kumar is currently a co-founder and the Chief Executive Officer of BridgeBio Pharma, Inc., where he has worked since April 2015. Dr. Kumar has also served as the Chief Executive Of…
of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act, whether made before or after the da…
Entry into a Material Definitive Agreement. On February 4, 2026 (the “ Closing Date ”), Maze Therapeutics, Inc. (the “ Company ”) entered into that certain Loan and Security Agreement (the “ Hercules Loan Agreement ”), by and among the Company, as borrower, the lenders from time to time party thereto, and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the lenders party thereto, which provides for a senior secured term loan facility in an ag…
Termination of a Material Definitive Agreement Termination of Banc of California Loan and Security Agreement In connection with the entry into the Hercules Loan Agreement, the Company’s Loan and Security Agreement, dated as of June 27, 2022, with Banc of California was terminated, effective as of February 2, 2026, and Banc of California’s security interest in the Company’s assets and property was released.
by reference. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 4, 2026 By: /s/ Courtney Phillips Courtney Phillips General Counsel and Corporate Secretary
of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act, whether made before or after the da…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 3, 2025, the Board of Directors (the “ Board ”) of Maze Therapeutics, Inc. (the “ Company ”) appointed Hervé Hoppenot as a Class II director and as the Chairman of the Board, effective October 6, 2025 (the “ Appointment Date ”). Mr. Hoppenot succeeds Dr. Charles Homcy as Chairman of the Board, and Dr. Homcy will continue to serve as a di…
Entry into a Material Definitive Agreement . Securities Purchase Agreement On September 10, 2025, Maze Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional and accredited investors (the “ Investors ”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “ Private Placement ”) an aggregate of (i) 4,000,002 shares (the “ Shares…
Regulation FD Disclosure . On September 11, 2025, the Company issued a press release announcing the Private Placement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on September 11, 2025, the Company issued a press release announcing results from its Phase 1 trial of MZE782. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K. The information furnished in this Item 7.01, including Exhibits 99.1 and 99.2…
of Form 8-K, is hereby incorporated by reference herein. Based in part upon the representations of the Investors in the Securities Purchase Agreement, the offering and sale of the Securities was made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”) and corresponding provisions of state securities or “blue sky” laws. The Securities have not been registered under the Securities Act or any state securities laws and may no…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On September 2, 2025, Maze Therapeutics, Inc. (the “ Company ”) announced that the Board of Directors of the Company (the “ Board ”) appointed Misbah Tahir as the Company’s Chief Financial Officer and “principal financial officer,” effective as of September 2, 2025 (the “ Appointment Date ”). Before joining the Company, Mr. Tahir served as the Chi…
of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act, whether made before or after the da…
of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act, whether made before or after the da…
of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act, whether made before or after the da…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.